arrow_back Civic Audit
Share share

Restoring Safeguards for Abortion Drugs: New Rules and Liability

This act aims to reinstate stricter regulations for the abortion drug mifepristone, potentially making it harder to access. It also introduces legal liability for entities that unlawfully provide the drug, causing harm, and bans its importation into the United States.
Key points
Requires the FDA to reinstate the risk evaluation and mitigation strategy (REMS) for mifepristone, identical to the June 2011 strategy, which may restrict its availability.
Establishes legal liability for entities (e.g., telehealth providers, pharmacies) for physical or mental harm to women caused by unlawfully imported or transported mifepristone.
Prohibits the importation of mifepristone into the United States, including mailing it to individuals.
article Official text account_balance Process page notifications_active Track this Bill
Status: Introduced
Civic Will
Checking votes...
I support
I oppose
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_HR_5646
Sponsor: Rep. Miller, Mary E. [R-IL-15]
Process start date: 2025-09-30
System Note: Lustra is free, publicly auditable civic infrastructure — full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source—always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Restoring Safeguards for Dangerous Abortion Drugs Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_5646.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-09-30.

What are the main provisions?

Key points include:

  • Requires the FDA to reinstate the risk evaluation and mitigation strategy (REMS) for mifepristone, identical to the June 2011 strategy, which may restrict its availability.
  • Establishes legal liability for entities (e.g., telehealth providers, pharmacies) for physical or mental harm to women caused by unlawfully imported or transported mifepristone.
  • Prohibits the importation of mifepristone into the United States, including mailing it to individuals.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Miller, Mary E. [R-IL-15].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

What is the impact of this bill?

We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Courts and Law